Modeling boron adsorption on five soils before and after removal of organic matter

Boron-B concentrations that cause deficiency and those that cause toxicity appear to be very similar, compared to other nutrients, which can complicate successful management of this element in soils. In this study, B adsorption onto two Oxisols from Brazil (Rhodic Eutroperox and Anionic Acroperox), two Alfisols (Natric Palexeralf and Aridic Paleustalf) and an Entisol (Xeric Torrifluvent) from the United States of America were evaluated. The samples were treated with sodium hypochlorite in order to remove soil organic matter. Both treated and untreated samples were used to determine B adsorption isotherms using different B concentrations (0- 4.630 mmol L–1) and NaNO3 (0.05 M) as background electrolyte solution at pH 7. Boron adsorption envelopes were also measured using 0.463 mmol L–1 B at three ionic strengths (0.05, 0.1 and 1M) and NaNO3 as background electrolyte solutions at different pH values (3-12). The cation exchange capacity, specific surface area, free Al and Fe oxides, organic and inorganic carbon content, mineralogy and particle size distribution of the soils were also determined. The Langmuir isotherm and the constant capacitance model were fit to the B adsorption data and the parameters obtained were related to the chemical attributes by multiple linear regression equations. Boron maximum adsorption capacity (BMAC) and the complexation constant for the SH3BO4 – inner-sphere complex (LogKB–) could be predicted under all experimental conditions. The Alc content was the main soil chemical attribute associated with the BMAC under the conditions evaluated and the LogKB–(int) in untreated and treated samples

LHC / ILC / Cosmology Interplay

There is a strong and growing interplay between particle physics and cosmology. In this talk, I discuss some aspects of this interplay concerning dark matter candidates put forth by theories beyond the Standard Model. In explaining the requirements for collider tests of such dark matter candidates, I focus in particular on the case of the lightest neutralino in the MSSM.Comment: 7 pages, contribution to the proceedings of the IX Workshop on High Energy Physics Phenomenology (WHEPP-9), 3-14 Jan 2006, Bhubaneswar, Indi

Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery

We report detailed susceptibility profiling of asexual blood stages of the malaria parasite Plasmodium falciparum to clinical and experimental antimalarials, combined with metabolomic fingerprinting. Results revealed a variety of stage-specific and metabolic profiles that differentiated the modes of action of clinical antimalarials including chloroquine, piperaquine, lumefantrine, and mefloquine, and identified late trophozoite-specific peak activity and stage-specific biphasic dose-responses for the mitochondrial inhibitors DSM265 and atovaquone. We also identified experimental antimalarials hitting previously unexplored druggable pathways as reflected by their unique stage specificity and/or metabolic profiles. These included several ring-active compounds, ones affecting hemoglobin catabolism through distinct pathways, and mitochondrial inhibitors with lower propensities for resistance than either DSM265 or atovaquone. This approach, also applicable to other microbes that undergo multiple differentiation steps, provides an effective tool to prioritize compounds for further development within the context of combination therapies

PfMFR3: A multidrug-resistant modulator in Plasmodium falciparum

In malaria, chemical genetics is a powerful method for assigning function to uncharacterized genes. MMV085203 and GNF-Pf-3600 are two structurally related napthoquinone phenotypic screening hits that kill both blood- and sexual-stag

Protocol for the saMS trial (supportive adjustment for multiple sclerosis): a randomized controlled trial comparing cognitive behavioral therapy to supportive listening for adjustment to multiple sclerosis

BackgroundMultiple Sclerosis (MS) is an incurable, chronic, potentially progressive and unpredictable disease of the central nervous system. The disease produces a range of unpleasant and debilitating symptoms, which can have a profound impact including disrupting activities of daily living, employment, income, relationships, social and leisure activities, and life goals. Adjusting to the illness is therefore particularly challenging. This trial tests the effectiveness of a cognitive behavioural intervention compared to supportive listening to assist adjustment in the early stages of MS.MethodsThis is a two arm randomized multi-centre parallel group controlled trial. 122 consenting participants who meet eligibility criteria will be randomly allocated to receive either Cognitive Behavioral Therapy or Supportive Listening. Eight one hour sessions of therapy (delivered over a period of 10 weeks) will be delivered by general nurses trained in both treatments. Self-report questionnaire data will be collected at baseline (0 weeks), mid-therapy (week 5 of therapy), post-therapy (15 weeks) and at six months (26 weeks) and twelve months (52 weeks) follow-up. Primary outcomes are distress and MS-related social and role impairment at twelve month follow-up. Analysis will also consider predictors and mechanisms of change during therapy. In-depth interviews to examine participants’ experiences of the interventions will be conducted with a purposively sampled sub-set of the trial participants. An economic analysis will also take place. DiscussionThis trial is distinctive in its aims in that it aids adjustment to MS in a broad sense. It is not a treatment specifically for depression. Use of nurses as therapists makes the interventions potentially viable in terms of being rolled out in the NHS. The trial benefits from incorporating patient input in the development and evaluation stages. The trial will provide important information about the efficacy, cost-effectiveness and acceptability of the interventions as well as mechanisms of psychosocial adjustment.Trial registrationCurrent Controlled Trials ISRCTN91377356<br/

Testing Yukawa-unified SUSY during year 1 of LHC: the role of multiple b-jets, dileptons and missing E_T

We examine the prospects for testing SO(10) Yukawa-unified supersymmetric models during the first year of LHC running at \sqrt{s}= 7 TeV, assuming integrated luminosity values of 0.1 to 1 fb^-1. We consider two cases: the Higgs splitting (HS) and the D-term splitting (DR3) models. Each generically predicts light gluinos and heavy squarks, with an inverted scalar mass hierarchy. We hence expect large rates for gluino pair production followed by decays to final states with large b-jet multiplicity. For 0.2 fb^-1 of integrated luminosity, we find a 5 sigma discovery reach of m(gluino) ~ 400 GeV even if missing transverse energy, E_T^miss, is not a viable cut variable, by examining the multi-b-jet final state. A corroborating signal should stand out in the opposite-sign (OS) dimuon channel in the case of the HS model; the DR3 model will require higher integrated luminosity to yield a signal in the OS dimuon channel. This region may also be probed by the Tevatron with 5-10 fb^-1 of data, if a corresponding search in the multi-b+ E_T^miss channel is performed. With higher integrated luminosities of ~1 fb^-1, using E_T^miss plus a large multiplicity of b-jets, LHC should be able to discover Yukawa-unified SUSY with m(gluino) up to about 630 GeV. Thus, the year 1 LHC reach for Yukawa-unified SUSY should be enough to either claim a discovery of the gluino, or to very nearly rule out this class of models, since higher values of m(gluino) lead to rather poor Yukawa unification.Comment: 32 pages including 31 EPS figure

Actes du Ve congrès national d'archéologie et d'histoire de l'art

Actes du Ve congrès national d'archéologie et d'histoire de l'art, qui s'est tenu à Bordeaux du 21 au 24 octobre 1999. Thématiques abordées : - Les portes de l'Espagne - Le mur et l'art - La critique architecturale aux XIXe et XXe siècles - Art éphémère - La place de l'histoire de l'art dans la synthèse historiqu

Prioritization of Molecular Targets for Antimalarial Drug Discovery

There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in Plasmodium species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In this paper, we describe the criteria that we consider important for selecting targets for antimalarial drug discovery. We describe the analysis of a number of drug targets in the Malaria Drug Accelerator (MalDA) pipeline, which has allowed us to prioritize targets that are ready to enter the drug discovery process. This selection process has also highlighted where additional data are required to inform target progression or deprioritization of other targets. Finally, we comment on how additional drug targets may be identified

Actes du Ve congrès national d'archéologie et d'histoire de l'art : Bordeaux, 21-24 octobre 1999

Actes du Ve congrès national d'archéologie et d'histoire de l'art, qui s'est tenu à Bordeaux du 21 au 24 octobre 1999. Thématiques abordées : - Les portes de l'Espagne - Le mur et l'art - La critique architecturale aux XIXe et XXe siècles - Art éphémère - La place de l'histoire de l'art dans la synthèse historiqu